Study | End Point | HR (95% CI) | P value | TWA Pos % | TWA Neg % | Cut-off value (μV) | Lead | Method |
---|---|---|---|---|---|---|---|---|
Sakaki et al. 2009 [19] | Cardiac mortality* | 17.1 (6.3–46.6) | P <0.0001 | 18 | 82 | 65 | V1 or V5 | MMA |
Sulimov et al. 2012 [20] | SCD | 5.01 (1.5–17.0) | 0.005 | 41 | 59 | 53.5 | - | MMA |
Yu et al. 2012 [21] | SCD | 15.07 (2.88-78.68) | 0.0031 | 22 | 88 | 47 | V2 or V5 | MMA |
Monasterio et al. 2012 [22] | Cardiac mortality | 1.44 (0.97–2.13) | 0.068 | 24 | 76 | 3 | - | LLR |
Hoshida et al. 2013 [18] | Fatal arrhythmic events | 5.8 (1.6–20.8) | 0.0072 | 5 | 95 | 64 | V1 or V5 | MMA |